All Eisai articles
-
BusinessSecond Alzheimer’s antibody approved in the US
Biogen–Eisai’s lecanemab can slow disease progression a little, but at significant cost and risk of side effects
-
Business
Alzheimer’s antibody engenders anticipation
Tantalising press-released data on Biogen and Eisai’s lecanemab prompt questions without firm answers
-
Business
BMS and Eisai agree antibody-drug conjugate commercialisation deal
Companies will jointly develop cancer treatment, with BMS paying up to $3 billion for shared rights
-
Business
Japanese pharma opens compound vaults
Molecule libraries to be screened for neglected diseases
-
News
FDA green lights new obesity drug
Agency approval for prescription only obesity drug is first for 13 years
